Abstract
Prostaglandin F 2α (PGF 2α) is rapidly metabolized in the human body following exogenous administration. Three main metabolites have been isolated and identified: 15-keto-PGF 2α, 15-keto-13, 14-dihydro-PGF 2α and 13, 14-dihydro-PGF 2α. One of these metabolites, 13, 14-dihydro-PGF 2α, stimulated human uterine contractility during midpregnancy both following intravenous and intra-amniotic administration. The activity approaches that of the parent compound, PGF 2α. Since the concentration of the metabolites in peripheral serum during continuous intravenous infusion of PGF 2α is only slightly lower than that found for PGF 2α, it is likely that 13, 14-dihydro-PGF 2α is of importance for the stimulatory effect of PGF 2α on human uterine activity in vivo. Intravenous injection of high doses of 15-keto-13, 14-dihydro-PGF 2α (2–4 mg) slightly stimulated uterine contractility but most likely this effect was not due to the compound itself but to the formation of its metabolite, 13, 14-dihydro-PGF 2α.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
